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Insulin-like growth factor I (IGF-I) accumulates in the kidney
following the onset of diabetes, initiating diabetic renal hyper-
trophy. Increased renal IGF-I protein content, which is not
reflected in messenger RNA (mRNA) levels, suggests that renal
IGF-I accumulation is due to sequestration of circulating IGF-I
rather than to local synthesis. It has been suggested that IGF-I is
trapped in the kidney by IGF binding protein 1 (IGFBP-1). We
administered purified human IGFBP-1 (hIGFBP-1) to nondiabetic
and diabetic mice as three daily sc injections for 14 days,
starting 6 days after induction of streptozotocin diabetes when
the animals were overtly diabetic. Markers of early diabetic renal
changes (i.e., increased kidney weight, glomerular volume, and
albuminuria) coincided with accumulation of renal cortical IGF-I
despite decreased mRNA levels in 20-day diabetic mice. Human
IGFBP-1 administration had no effect on increased kidney
weight or albuminuria in early diabetes, although it abolished
renal cortical IGF-I accumulation and glomerular hypertrophy in
diabetic mice. Increased IGF-I levels in kidneys of normal mice
receiving hIGFBP-1 were not reflected on kidney parameters.
IGFBP-1 administration in diabetic mice had only minor effects
on diabetic renal changes. Accordingly, these results did not
support the hypothesis that IGFBP-1 plays a major role in early
renal changes in diabetes. Exp Biol Med 230:135–143, 2005
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L
ong-term diabetes is accompanied by diabetic ne-
phropathy in 15%–20% of patients with type 1
diabetes, and diabetic nephropathy is one of the most
frequent causes of end-stage renal failure in developed
countries (1). Increased kidney size, glomerular volume, and
hyperfiltration are followed by an increase in urinary
albumin excretion, mesangial proliferation, and accumula-
tion of extracellular matrix. Progressive glomerular sclerosis
leads to proteinuria and progressive renal insufficiency. The
involvement of the growth hormone (GH)/insulin-like
growth factor (IGF) axis in diabetic renal complications
has been recognized for a long time (2).
IGF-I is a multifunctional polypeptide produced under
the influence of pituitary GH (3). The liver produces most of
the circulating IGF-I, although physiologically important
autocrine and paracrine production occurs within other
tissues. The biological functions of IGF-I are mediated by
cell surface receptors, particularly by the IGF-I receptor
(IGF-IR, also known as the Type 1 IGF receptor). Six high-
affinity IGF binding proteins (IGFBP-1 to IGFBP-6)
modulate the actions of IGF-I (4). Circulatory IGFBPs
carry the major portion of serum IGF-I, neutralizing its
hypoglycemic potential, prolonging its half-life, and trans-
porting it to target tissues. Locally synthesized IGFBPs
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modulate the biological effects of IGF-I at the receptor level.
In addition, IGFBPs may also have ligand-independent
effects (4).
Morphologic and hemodynamic renal changes that
occur in the insulinopenic diabetes model produced by
streptozotocin (STZ), reflect the changes observed in the
course of type 1 diabetes in humans. Following the onset of
diabetes, IGF-I accumulates in the kidney, preceding the
initiation of renal hypertrophy (5–7). An increased kidney
IGF-I protein content, along with unchanged or decreased
IGF-I messenger RNA (mRNA) levels, suggest that renal
IGF-I accumulation is due to sequestration of circulatory
IGF-I rather than to local synthesis (6).
IGF-I may get trapped in the kidney as a consequence
of changes in renal IGFBPs. IGFBP-1 is considered a strong
candidate both in capturing IGF-I locally and in mediating
kidney growth per se. IGF-I and IGFBP-1 colocalize in the
same portions of the nephron, in the same cell types,
supporting the view that the actions of IGF-I may be
modified by IGFBP-1 (8). In early STZ-induced diabetes in
rats, cortical IGFBP-1 mRNA is increased (9).
Recently, we reported increased kidney weights after
human IGFBP-1 (hIGFBP-1) administration in pituitary-
deficient Snell dwarf mice. In addition, hIGFBP-1 coad-
ministered with IGF-I neutralized the stimulating effects of
IGF-I on body length and weight, but not on kidney weight
(10). These results, suggesting an important role for
IGFBP-1 in kidney enlargement, led us to investigate the
effects of hIGFBP-1 administration on kidney parameters
and regulation of the GH/IGF axis in a diabetic mouse
model.
Materials and Methods
Human IGFBP-1 Isolation and Purification. Hu-
man IGFBP-1 was isolated from midgestational amniotic
fluid obtained for diagnostic purposes with approval of the
Ethics Committee of Sophia Children’s Hospital, Rotter-
dam, The Netherlands, and purified on a Resource RPC 3-
ml column connected to a fast protein liquid chromatog-
raphy (FPLC) System (Automatic FPLC; Pharmacia Bio-
tech, Uppsala, Sweden) as described in detail previously
(11).
Animals and Procedures. Adult female NMRI
mice aged 8 weeks (Bomholtgaard, Ry, Denmark) with
initial body weights of 21.3 6 0.9 g were used. Mice were
housed five to six per cage and had free access to standard
chow (Altromin 1324; Lage, Germany) and tap water. They
were kept at constant temperature (228 6 28C) and humidity
(55% 6 2%), under a 12:12-hr light:dark cycle (0600–1800
hrs). The study complied with Danish regulations for
handling laboratory animals.
The animals were randomized into four groups, two of
which were made diabetic: (i) control/placebo (CP, n = 10),
(ii) control/hIGFBP-1 (CI, n = 10), (iii) diabetic/placebo
(DP, n = 15), and (iv) diabetic/hIGFBP-1 (DI, n = 15). After
12 hrs of food deprivation (all groups), diabetes was
induced at Day 0 by a single iv tail-vein injection of STZ
(&225 mg/kg body weight) dissolved in 0.154 M NaCl (pH
4). The animals were weighed, blood glucose levels were
measured in tail-vein blood (Precision Xtra; Abbott
Laboratories, MediSense Products, Bedford, MA), and
urine was examined for glucose and ketone bodies (Neo-
stix-4; Ames, Stoke Poges, Slough, UK) every second day
throughout the study. Mice with ketonuria on Day 3 were
treated with sustained release insulin implants (Linbit for
mice; Linshin Canada, Inc., Scarborough, ON, Canada) to
correct ketonuria and prevent massive body weight loss.
Mice with blood glucose levels greater than 16 mM and
without ketonuria were included in the study.
Human IGFBP-1 administration was initiated at Day 6,
when the animals developed overt diabetes. Human IGFBP-
1 was administered by three daily sc injections (at 0800,
1600, and 2400 hrs) for 14 days (0.3 mg hIGFBP-1/animal/
day, based on previous study; Ref. 10), while placebo
groups received an equivalent volume of vehicle alone
(0.154 M NaCl) in the same time intervals (Days 6–19).
Food consumption was measured per cage and expressed
per mouse. Animals were sacrificed at Day 20 after sodium
barbital (10 mg/kg body weight) ip anesthesia, exactly 2 hrs
after the last hIGFBP-1 injection. Blood was drawn 5 mins
later from the retro-orbital venous plexus. Serum was stored
at 808C until analysis. Immediately after extraction,
kidneys and liver were weighed, snap-frozen in liquid
nitrogen, and stored at 808C. The middle part of the left
kidney (2 mm thick) containing the papilla was fixed and
embedded in paraffin for morphological measurements and
immunohistochemistry.
Immunoassays. Serum GH, serum IGF-I, and renal
cortical IGF-I levels were measured by radioimmunoassay
as described previously (12). Serum insulin was measured
by an ultrasensitive rat insulin enzyme-linked immunosorb-
ent assay (DRG Diagnostics, Marburg, Germany). Semilog
linearity of mouse serum and rat insulin was found at
multiple dilutions, indicating antigen similarity between
mouse and rat insulin. The intraassay and interassay
coefficients of variation were,5% and,10%, respectively.
Western Ligand Blotting (WLB) for Determina-
tion of Serum and Kidney IGFBPs. Serum samples (2
ll per lane) or tissue homogenates (200 lg per lane) were
separated by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS-PAGE) and WLB analysis of serum
and renal cortical IGFBPs was executed as described
previously (13). The relative densities of the bands were
expressed in pixels.
Western Immuno Blotting (WIB) for IGFBP-1
and IGFBP-2. Serum samples (2 ll per lane) were
separated by SDS-PAGE (15% polyacrylamide) and trans-
ferred by electroelution onto nitrocellulose membrane
(Schleicher & Schuell, Munich, Germany). The blots were
blocked for 12 hrs at 48C in 5% nonfat milk and incubated
overnight at 48C with a polyclonal goat IGFBP-1 antibody
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(Santa Cruz Biotechnology, Santa Cruz, CA) in a dilution of
1/1000, or with a polyclonal goat IGFBP-2 antibody (Santa
Cruz Biotechnology) in a dilution of 1/1000. The IGFBP-1
antibody cross-reacts both with human and mouse IGFBP-1
(mIGFBP-1). After washing in Tris-buffered saline–Tween
(0.1%), the membranes were incubated with an anti-goat
IgG antibody conjugated with horseradish peroxidase
(Pierce, Rockford, IL) for 1 hr at room temperature in a
dilution of 1/12,000. The bands were visualized by
chemiluminescence (BioWest; UPV Inc., Upland, CA) and
quantified by a UPV BioImaging System (UPV Inc.).
Immunohistochemistry. The middle part of the left
kidney (2 mm thick) containing the papilla was fixed in
neutral buffered 4% paraformaldehyde and embedded in
paraffin. Four-micrometer-thick sections were prepared by
standard techniques and mounted on SuperFrost Plus slides
(Fisher Scientific, Fairlawn, NJ). Tissue sections were then
deparaffinized and rehydrated. Kidney sections were
incubated with a polyclonal antibody against human IGF-I
(a kind gift from Dr. Peter Gluckman, Liggins Research
Institute, Auckland, New Zealand; 14) for 24 hrs at 48C. The
immunoreactivity was visualized by the avidin-biotin-
peroxidase technique, using diaminobenzidine as the
chromagen (Vectastain; Vector Laboratories, Burlingame,
CA). The tissue sections were then counterstained with
Carazzi’s hematoxylin, dehydrated, and mounted with
Permount (Fisher Scientific).
Real-t ime Polymerase Chain Reaction
(PCR). Total RNA was extracted from cortical kidney
and liver samples by Trizol Reagent following the
instructions of the manufacturer (Gibco BRL–Life Tech-
nologies Inc., Gaithersburg, MD). Renal cortical and hepatic
GH/IGF system gene expression was analyzed by means of
real-time quantitative PCR (TaqMan), as described previ-
ously (11). Following complementary DNA synthesis,
mRNA levels were quantitatively determined on an ABI
Prism 7700 Sequence Detection system (Applied Biosys-
tems, Foster City, CA) using SYBR-green technology. The
primers used for mouse hypoxanthine phosphoribosyltrans-
ferase (mHPRT), mIGF-I, mIGFBP-1, mIGFBP-3, mouse
growth hormone-receptor (mGHR), and mouse growth
hormone binding protein (mGHBP) have been reported
previously (11). The primer set used for mIGFBP-2 was
forward primer, CGCGGGTACCTGTGAAAAGA and
reverse primer, CCCTCAGAGTGGTCGTCATCA, result-
ing in an amplicon size of 77 base pairs (bp). The primer set
used for mIGFBP-4 was forward primer, CATCCC-
CATTCCAAACTGTGA and reverse primer, AC-
CCCTGTCTTCCGATCCA, resulting in an amplicon size
of 110 bp. The primer set used for mIGFBP-5 was forward
primer, AGACCTACTCCCCCAAGGTCTT and reverse
primer, TTTCTGCGGTCCTTCTTCACA, resulting in an
amplicon size of 84 bp. The primer set used for mIGF-IR
was forward primer, GGGATTTCTGCGCCAACA and
reverse primer, CGTGGATGACGAAGCCATCT, resulting
in an amplicon size of 62 bp.
PCR efficiencies for all primer sets were .95%. All
measured values were normalized to mHPRT gene
expression.
Estimation of Glomerular Volume. The middle
part of the left kidney (2 mm thick) containing the papilla
was fixed in 2% paraformaldehyde, 2.5% glutaraldehyde,
and 0.1 M cacodylate buffer, and embedded in paraffin.
Sections (2 lm) cut on a rotation microtome (Leica Rotation
Microtome RM 2165; Leica, Vienna, Austria) were stained
with periodic acid–Schiff and hematoxylin. The thickness of
the sections was controlled routinely by a Digital Microcator
ND 221 (Heidenhain, Traunreut, Germany) attached to the
microscope. In each animal, the mean glomerular tuft
volume (VG) was determined from the mean glomerular
cross sectional area (AG) by light microscopy at a
magnification of 340 as previously described (12). Profile
areas were determined with a two-dimensional version of
the nucleator (CAST; Olympus, Copenhagen, Denmark).
AG was determined as the average area of a total of 40 to 50
glomerular profiles (capillary tuft omitting the proximal
tubular tissue within the Bowman capsule) and VG was
calculated from the following equation: VG = b/k3 (AG)
3/2,
where b = 1.38 is the shape coefficient for spheres (the
idealized shape of glomeruli), and k = 1.1 is a size
distribution coefficient. The measurements were performed
in a blinded fashion without the investigator’s knowledge of
the different groups.
Urinary Albumin and Creatinine Concentra-
tion. The urine samples were collected in the morning
(0800–1100 hrs) by gentle massage over the lower part of
the abdomen and stored at 208C until analysis was
performed. The urinary albumin concentration was deter-
mined by radioimmunoassay as previously described (12).
The urinary creatinine concentration was measured by an
automated technique adapted from the Jaffe´ reaction and
corrected for the prevailing glucose content due to
interference in the Jaffe´ reaction. The intraassay and
interassay coefficients of variation were ,5% and ,10%,
respectively, for both assays.
Statistical Analysis. Means were compared by one-
way ANOVA followed by pairwise comparisons with the
least significant difference method. Serum GH values ,1.3
were assigned value 1.3, and four groups were tested by a
Kruskal-Wallis test, followed by pairwise comparisons by a
Mann-Whitney test (SPSS software package; SPSS Inc.,
Chicago, IL). Results are given as the mean 6 SEM, with n
indicating the number of animals studied. Significance was
assigned at P  0.05.
Results
Body Weight and Metabolic Parameters. Body
weights of mice from control groups steadily increased over
the time of the study (Fig. 1A). Diabetic mice weighed
significantly less than their respective control groups at all
time points considered throughout the study, despite a
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significantly higher daily food consumption (Fig. 1C). At
Day 2, blood glucose levels in diabetic animals were
approximately 3-fold higher than in controls and remained
elevated throughout the study period (Fig. 1B). Insulin
levels at Day 20 were lower in both diabetic groups
compared with their respective controls (Fig. 2C). Injected
hIGFBP-1 did not have any influence on mentioned
parameters in the control and diabetic groups. Blood
glucose levels were significantly decreased in diabetic mice
administered hIGFBP-1 only in the last time point measured
(P = 0.016).
Serum GH, IGF-I, and IGFBPs. In diabetic animals,
serum GH levels were significantly increased (Fig. 2A) and
IGF-I levels were decreased (Fig. 2B). Whereas hIGFBP-1
had no additional effect on GH serum levels, it further
decreased IGF-I serum levels (Fig. 2A and B).
Serum levels of IGFBP-1, detected by WLB, were
markedly higher in animals injected with hIGFBP-1, but
significantly less elevated in the diabetic group than in the
control group (Fig. 2D). On WIB, injected hIGFBP-1 and
endogenous mIGFBP-1 were clearly distinguishable by size
(Fig. 2E). Mouse IGFBP-1 levels were not different
between the groups. Circulating IGFBP-2 levels, detected
both on WLB and WIB, were significantly elevated in
diabetic animals receiving hIGFBP-1 compared with all
other groups (Fig. 2D and E). Serum IGFBP-3 values were
lower in diabetic animals compared with their respective
controls, and were significantly reduced by hIGFBP-1
injections in both control and diabetic groups (Fig. 2D).
Serum IGFBP-4 levels were decreased in both diabetic
groups and were significantly increased in normal mice
injected with hIGFBP-1 (Fig. 2D).
Kidney Weight, Glomerular Volume, and Uri-
nary Albumin Excretion. Kidney weight is represented
as the mean value of both kidneys (Fig. 3A). Kidneys of
diabetic mice were significantly heavier than kidneys of
their respective nondiabetic controls. Administration of
hIGFBP-1, both in the control and diabetic groups, did not
have any effect on kidney weight.
Glomerular volume was increased as a consequence of
the diabetic state, and injection of hIGFBP-1 decreased it
significantly (Fig. 3B). As an indicator of proteinuria the
albumin:creatinine ratio (mg/mmol) was calculated. This
ratio was increased in diabetic mice (Fig. 3C). The effect of
hIGFBP-1 was not statistically significant.
Kidney IGF-I and IGFBPs. Extractable IGF-I pro-
tein content was increased in the renal cortex of diabetic
mice receiving placebo (Fig. 4A). In diabetic mice
receiving hIGFBP-1, IGF-I protein content was reduced
(Fig. 4A). Human IGFBP-1 administration increased IGF-I
levels in the kidneys of normal mice (Fig. 4A). Immunos-
tainable IGF-I was clearly visible in both diabetic groups,
but was absent in both nondiabetic groups. In diabetic
kidneys, IGF-I was predominantly localized in papillary
collecting ducts (Fig. 4C) and to some extent in cortical
collecting ducts.
Renal cortical IGFBP-1 protein levels were markedly
increased in groups receiving hIGFBP-1, and they were
higher in diabetic group than in control group (Table 1 and
Fig. 4B). IGFBP-2 protein content was higher in kidneys of
diabetic animals receiving hIGFBP-1 compared with that of
all groups (Table 1). Renal cortical IGFBP-3 protein levels
were decreased in both diabetic groups (Table 1). The renal
cortical IGFBP-4 protein level was decreased in diabetic
mice receiving placebo, with an increase due to hIGFBP-1
administration (Table 1).
Expression of the GH/IGF Axis Genes in Kidney
and Liver. Renal cortex IGF-I mRNA concentration was
significantly reduced in both diabetic groups (Fig. 5).
IGFBP-1 mRNA levels were increased in the control group
receiving hIGFBP-1 and decreased in both diabetic groups
(Table 1 and Fig. 5). Cortical expression of IGFBP-2
mRNA in kidney was not significantly different between the
groups (Table 1). Renal mRNA expression of IGFBP-3 to
Figure 1. (A) Body weight, (B) blood glucose, and (C) food
consumption in nondiabetic mice injected with placebo (L) or
hIGFBP-1 (&) and diabetic mice injected with placebo (n) or
hIGFBP-1 (). Values are given as means (n = 10 for control, n =
15 for diabetic groups).
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IGFBP-5 was decreased in both diabetic groups (Table 1).
Levels of renal IGF-IR mRNA were significantly lower in
all groups compared with the CP group (P , 0.001, data
not shown). Expression of GH receptor mRNA was
decreased in the control group receiving hIGFBP-1 (P =
0.018, CI vs. CP) and in the diabetic group receiving
placebo (P = 0.014, DP vs. CP, data not shown). GH
binding protein mRNA levels were decreased in kidneys of
both diabetic groups (P  0.001, DP vs. CP and DI vs. CI,
data not shown).
Hepatic IGF-I mRNA was down-regulated in diabetes
and up-regulated in normal mice receiving hIGFBP-1 (P 
0.005, DP vs. CP; P  0.05, DI vs. CI; P  0.05, CI vs. CP,
data not shown). Liver IGFBP-1 mRNA levels were
Figure 2. (A) Serum growth hormone (GH), (B) IGF-I, (C) insulin, and (D) IGFBPs (WLB) levels at Day 20 in nondiabetic mice injected with
placebo (CP, white bars) or hIGFBP-1 (CI, light shaded bars), and diabetic mice injected with placebo (DP, dark shaded bars) or hIGFBP-1 (DI,
black bars). Values are means6 SEM (n = 10 for control, n = 15 for diabetic groups)...P  0.005;.P  0.05 vs. CP group; ##P  0.005; #P
 0.05 vs. CI group; P  0.005; P  0.05 vs. DP group. Serum IGFBP-1 (hIGFBP-1, 29 kDa; mIGFBP-1, 27 kDa) and IGFBP-2 (34 kDa)
by WIB in CP (lanes 1–3), CI (lanes 4 and 5), DP (lanes 6–8), and DI (lanes 9–11) groups (E).
Figure 3. (A) Kidney weight, (B) glomerular volume, and (C) urinary albumin excretion at Day 20 in nondiabetic mice injected with placebo (CP,
white bars) or hIGFBP-1 (CI, light shaded bars) and diabetic mice injected with placebo (DP, dark shaded bars) or hIGFBP-1 (DI, black bars).
Values are means6 SEM (n = 10 for control, n = 15 for diabetic groups)..P  0.005 vs. CP group, #P  0.001 vs. CI group,P  0.05 vs. DP
group.
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significantly increased in diabetic animals receiving
hIGFBP-1 compared with those in all groups (P  0.05,
data not shown). IGFBP-2 mRNA concentration was
elevated in diabetic livers (P , 0.001, DP vs. CP; P =
0.007, DI vs. CI, data not shown). Hepatic IGFBP-3 mRNA
was decreased in diabetic mice (P = 0.001, DP vs. CP) and
restored to control levels when hIGFBP-1 was injected (P =
0.013, DI vs. DP, data not shown). Levels of IGFBP-4 and
IGFBP-5 mRNA were not different between the groups
(data not shown). Expression of GH receptor and GH-
binding protein mRNA was decreased in livers of both
diabetic groups (P  0.001, DP vs. CP and DI vs. CI, data
not shown).
Discussion
The major new finding of this study is that hIGFBP-1
administered for 2 weeks to mice with early STZ-diabetes
had no further effect on the increase in kidney weight and
albuminuria. However, hIGFBP-1 administration abolished
the renal IGF-I accumulation and the increase in glomerular
volume in diabetic animals.
The majority of previously published data on the
involvement of the IGF system in diabetic renal hypertrophy
have been obtained in the STZ-diabetic rat model, which is
characterized by growth hormone hyposecretion (2). In
contrast, as recently described, the STZ-diabetic mouse
model is characterized by GH hypersecretion, thereby being
Figure 4. (A) Kidney IGF-I and (B) IGFBP-1 levels and immunostainable IGF-I in papillary collecting ducts (320) (C) at Day 20 in nondiabetic
mice injected with placebo (CP, white bars) or hIGFBP-1 (CI, light shaded bars) and diabetic mice injected with placebo (DP, dark shaded bars)
or hIGFBP-1 (DI, black bars). Values are means 6 SEM [n = 10 for control, n = 15 for diabetic groups (A); n = 9 (B)]..P  0.005 vs. CP group;
##P  0.005; #P  0.05 vs. CI group; P  0.001 vs. DP group.
Table 1. Kidney IGFBPs mRNA and Protein Levels at Day 20 in Nondiabetic and Diabetic Mice Injected with
Placebo or hIGFBP-1a
Messenger RNAb Proteinc
Kidney CP CI DP DI CP CI DP DI
IGFBP-1 1 6 0.11 1.81 6 0.25* 0.54 6 0.09* 0.3 6 0.05** 46.8 6 4.8 176.5 6 27.5* 30.6 6 2.3 334.4 6 45.6**,***
IGFBP-2 1 6 0.15 0.86 6 0.14 0.73 6 0.09 0.81 6 0.12 357.8 6 20.2 358 6 22 334.4 6 22 485.9 6 29**,***
IGFBP-3 1 6 0.05 1.04 6 0.1 0.47 6 0.02* 0.4 6 0.04** 331.8 6 28.5 318.5 6 14.6 197.9 6 14.9* 189.7 6 8**
IGFBP-4 1 6 0.09 0.9 6 0.08 0.46 6 0.06* 0.41 6 0.04** 160 6 12 136.5 6 13.5 79.5 6 3* 113.9 6 9.7***
IGFBP-5 1 6 0.06 0.85 6 0.12 0.65 6 0.05* 0.6 6 0.03**
a CP, Nondiabetic mice injected with placebo; CI, nondiabetic mice injected with hIGFBP-1; DP, diabetic mice injected with placebo; DI,
diabetic mice injected with hIGFBP-1. Values are means 6 SEM (mRNA, n = 10; protein, n = 9).
b Artificial values, CP value set as 1.
c Protein levels are presented as pixel intensity.
*P  0.05 vs. CP group; **P  0.05, vs. CI group; ***P  0.05 vs. DP group.
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a better model of the changes observed in type 1 diabetes in
humans (12). It has been established for a long time that
IGF-I accumulates in diabetic kidneys undergoing hy-
pertrophy; however, increased renal IGF-I levels normalize
within 4 days after diabetes induction in the STZ rat model,
whereas they remain increased up to 4 weeks after diabetes
onset in the diabetic mouse (5, 12, 15). Renal IGF-I
accumulation occurs despite unchanged or reduced renal
IGF-I mRNA levels, indicating that IGF-I is taken up from
the circulation rather than produced locally (6, 9, 16, 17).
IGFBP-1, which is elevated in diabetic serum, is believed to
have a major role in sequestering circulating IGF-I. While
renal IGF-I accumulation in diabetic animals coincided with
increased kidney weight, increased glomerular volume, and
impairment of the kidney function reflected in higher
urinary albumin excretion, none of these changes were
observed in nondiabetic mice receiving hIGFBP-1.
Although administration of hIGFBP-1 to diabetic mice
affected neither the increase in kidney weight nor urinary
albumin excretion, it abolished the increase in glomerular
volume and blunted renal IGF-I accumulation. This suggests
that the renal weight and glomerular volume could be
affected by different mechanisms. Human IGFBP-1 admin-
istration may affect other relevant factors operating locally
in the glomerulus. In line with this, it is of interest that the
glomerular hypertrophy observed in both diabetic animals
and in those fed high-protein diets, is vascular endothelial
growth factor (VEGF)-dependent and that VEGF has been
suggested to be a downstream mediator of IGF-I effects
(18).
In the present study, renal IGF-I levels were increased
in diabetic mice and in nondiabetic mice after hIGFBP-1
administration, although renal IGF-I mRNA levels were
down-regulated or unchanged, respectively. Because all
samples were collected at Day 20 after diabetes onset, it
cannot be excluded that a transient increase in renal IGFBP-
1 at a time point before Day 20 would play a role in the
renal IGF-I accumulation observed in the diabetic kidney.
Renal IGF-I content was decreased in diabetic mice after
hIGFBP-1 administration. Administration of hIGFBP-1 did
not change serum IGF-I levels in control animals, but it did
decrease serum IGF-I levels in diabetic animals. Theoret-
ically, the observed lack of effect of IGFBP-1 adminis-
tration on renal IGF-I accumulation in diabetic mice could
be due to lower serum IGF-I levels combined with very high
serum IGFBP-1 levels, leading to reduced renal IGF-I
uptake.
Both protein content and mRNA levels of IGFBPs were
generally unchanged or decreased in the STZ diabetic
mouse kidney. This is in contrast with studies reporting
increased protein (30 kDa band; IGFBP-1, IGFBP-2, or
both) and mRNA levels of IGFBP-1 in 3- to 4-week non-
obese diabetic mouse kidney (15, 16, 19). Detailed
investigation of IGFBP mRNA patterns in the diabetic rat
kidney showed a reduction in IGFBP-1 expression in the
medulla and an increase in the cortex both in short-term (9,
17) and long-term diabetes (9). Our findings are in
agreement with studies describing a decrease in renal
IGFBP-3 to IGFBP-5 mRNA levels, both in rats and mice
(9, 15, 17). Human IGFBP-1 administration increased the
protein content of IGFBPs -1, -2, and -4, whereas it did not
change the IGFBPs mRNA expression pattern in the
diabetic kidney. In general, unchanged or decreased renal
protein content and renal expression of IGFBPs in the STZ
diabetic mouse suggest that IGF-I is captured in the kidney
by mechanism not involving IGFBPs.
Immunohistochemical studies detected IGFBP-1 colo-
calized with IGF-I predominantly in the papillary collecting
ducts, but also in cortical collecting ducts and medullary
thick ascending limbs of Henle’s loop in the rat kidney (8).
Immunostainable IGFBP-1 shows the same distribution in
the mouse kidney (unpublished data). We were not able to
specifically detect exogenous hIGFBP-1 due to lack of a
suitable human-specific IGFBP-1 antibody. Although ex-
tractable renal IGF-I was decreased in diabetic mice and
increased in normal mice following hIGFBP-1 administra-
tion, we were unable to clearly observe these changes on the
immunostained kidney sections. This may be due to the
difficulties in using immunohistochemistry for quantifica-
tion.
Our main aim was to investigate the effect of IGFBP-1
on early changes that take place in the diabetic kidney.
Limited availability of purified hIGFBP-1 allowed us only
to assess the effect of 2 weeks of hIGFBP-1 administration
in early diabetes. Although minipumps would be a more
appropriate route for administering hIGFBP-1, they would
be insufficient to sustain the required high hIGFBP-1 levels.
Because hIGFBP-1 administration in pituitary-deficient
Figure 5. Expression of IGF-I and IGFBP-1 mRNA in kidney at Day
20 in nondiabetic mice injected with placebo (CP, white bars) or
hIGFBP-1 (CI, light shaded bars) and diabetic mice injected with
placebo (DP, dark shaded bars) or hIGFBP-1 (DI, black bars). Values
are means6 SEM (n = 10)...P  0.005;.P  0.05 vs. CP group;
##P  0.005 vs. CI group.
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Snell dwarf mice resulted in a pronounced increase in
kidney weight (152%; Ref. 10), a comparable dose with
respect to body weight and the same administration route
was used (i.e., three daily sc injections). However, in the
present study, hIGFBP-1 did not have any major effects,
although increased levels of IGFBP-1 were detected in
injected mice, both in serum and kidney. It is possible that
in Snell dwarf mice, which lack endogenous GH, and
subsequently have very low IGF-I circulatory levels,
administered hIGFBP-1 was able to disturb the fragile
balance in the GH/IGF axis, whereas in normal mice and
diabetic mice, this was not the case. It may be that changes
taking place in the diabetic kidney, regarding increased
weight and decreased function, are already taking place at a
maximal level, so that no effect of IGFBP-1 administration
is observed. Further, it cannot be excluded that prolonged
administration of hIGFBP-1 would show some additional
effect, but in this study, we focused specifically on early
renal changes.
Another concern might be the phosphorylation state of
the hIGFBP-1 preparation used. It has been shown that
elevated serum IGFBP-1 in untreated diabetic patients exists
in the highly phosphorylated (p) state (20), a form that in
vitro has 4-fold to 6-fold higher affinity for IGF-I than the
nonphosphorylated (np) form (21). Although one might
argue that npIGFBP-1 is less important than pIGFBP-1, a
role for npIGFBP-1 in the regulation of free IGF-I in vivo
has been suggested (22). The purified hIGFBP-1 we
administered was approximately 50% phosphorylated and
shown to have renal effects in Snell dwarf mice (10). A
recent study involving hIGFBP-1 transgenic (TG) mice and
rat (r) IGFBP-1 TG mice exhibiting predominantly np and p
form in the serum, respectively, suggested that the
phosphorylation state of IGFBP-1 may account for part of
the phenotypic differences such as fasting hyperglycemia
and growth restriction in rIGFBP-1 TG but not in hIGFBP-1
TG mice (23). However, another line of hIGFBP-1 TG mice
did exhibit growth retardation and glucose intolerance,
although to a lesser extent than rIGFBP-1 TG mice,
suggesting that if predominantly nonphosphorylated or
lesser phosphorylated forms are present in sufficient
concentration, hIGFBP-1 could still have an effect (23,
24). It would be interesting in future experiments to study
renal changes in diabetic IGFBP-1 TG mice, as well as in
IGFBP-1 knockout mice.
In conclusion, hIGFBP-1 administration was shown not
to have major effects on early renal changes in diabetes.
Further studies are needed to describe the alterations in
IGFBPs in the diabetic kidney over time and especially to
determine their pathophysiological importance. Some of
these questions may be addressed in kidney-specific
IGFBPs TG and knockout diabetic mice.
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